Dr. Cicero is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
LG-650
Seattle, WA 98109Phone+1 855-557-0555
Summary
- Dr. Kara Cicero is an oncologist in Seattle, WA and is affiliated with Fred Hutchinson Cancer Center. She received her medical degree from Tulane University School of Medicine and has been in practice 7 years. She specializes in hematologic oncology and is experienced in multiple myeloma, AL amyloidosis, and other related plasma cell disorders. She has 8 publications and 17 citings.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 2020 - 2023- New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2017 - 2020
Tulane University School of Public Health & Tropical MedicineMPH, Global Health Systems & Development, 2013 - 2017- Tulane University School of MedicineMD, Alpha Omega Alpha Honor Medical Society, 2013 - 2017
Tulane University School of MedicineClass of 2017- Cornell UniversityBS, Human Development, Cum Laude, 2008 - 2012
Certifications & Licensure
MT State Medical License 2024 - 2026
WA State Medical License 2023 - 2026
NY State Medical License 2020 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Young Investigator Award Conquer Cancer Foundation, American Society of Clinical Oncology, 2022
- Cancer Disparities Research Fellowship American Association for Cancer Research, 2022
- Herbert Irving Comprehensive Cancer Center Trainee Associate Membership Postdoctoral Pilot Award Columbia University Medical Center / New York Presbyterian, 2021
- Join now to see all
Publications & Presentations
PubMed
- Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions.Kara I Cicero, Rahul Banerjee, Mary Kwok, Danai Dima, Andrew J Portuguese
Diagnostics. 2025-01-18 - 8 citationsDefiners and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling.Rahul Banerjee, Kara I Cicero, Sarah S Lee, Andrew J Cowan
Frontiers in Oncology. 2023-01-01 - 2 citationsPrevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men.Kara I Cicero, Maureen Joffe, Moosa Patel, Codruta Chiuzan, Audrey Pentz
Cancer Epidemiology, Biomarkers & Prevention. 2022-12-05
Abstracts/Posters
- Prevalence of Monoclonal Gammopathy of Undetermined Significance in Eswatini: A Study of an African PopulationCicero KI, Dlamini X, Mavengere Y, et al., American Society of Hematology, San Diego, CA, 2023
- The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma• Cicero KI, Neugut AI, Doyle AH, Bhutani D, Assal A, Reshef R, Mapara MY, Lentzsch S, Chakraborty R., American Society of Hematology, New Orleans, LA, 2022
- Combination Thioguanine and Decitabine is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution ExperienceCicero K, Heaney ML, Rosenblat TL, Lamanna N, Jurcic JG, Frattini MG, Lee DJ., American Society of Hematology, Orlando, FL, 2019
Grant Support
- Cancer Disparities Research FellowshipAmerican Association for Cancer ResearchPresent
- Young Investigator AwardConquer Cancer Foundation, American Society of Clinical OncologyPresent
- Herbert Irving Comprehensive Cancer Center Trainee Associate Membership Postdoctoral Pilot AwardColumbia University Medical Center / New York PresbyterianPresent
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
